Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Mutant Alleles of Hsp90 that Modulate the Lifespan of Yeast

This invention identifies Hsp90 mutant residues that affect the chronological lifespan of yeast.

Full description

Heat shock protein 90 (Hsp90) are a class of chaperone proteins that are up-regulated in response to elevated temperature and other environmental stresses. They act as chaperones to other cellular proteins and facilitate their proper folding and repair, and aid in the refolding of misfolded client proteins.

This invention identifies Hsp90 mutant residues that affect the chronological lifespan of yeast. These mutations in addition to a deletion in the sch9 allele, the yeast homolog to human kinase AKT, can increase yeast lifespan from 45 to 57 days, approximately 20% longer than the wildtype strain. These genetically engineered yeast strains may have the longest chronological lifespan reported to date.

Applications:
  • Model to study aging and longevity factors
  • Model to screen compounds that affect lifespan
  • A long-lived yeast strain could be used to ferment alcohol in a more efficient and cost effective as an alternative fuel source
  • Method to extend lifespan of transgenic farm animals
Market:
Anti-aging and alternative fuel industries are worth billions of dollars.

Related Publication:
BT Scroggins et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007 Jan 12;25(1):151-159. [PubMed abs]

Development status

Preclinical

Patent information

U.S. Provisional Application No. 60/848,346 filed 09 Sep 2006 (HHS Reference No. E-319-2006/0-US-01)

Inventors:
Bradley T. Scroggins (NCI) et al.

Type of business relationship sought

Licensees Sought:
Available for non-exclusive licensing.

Collaborative Research Opportunity:
The National Cancer Institute’s Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize models to study aging and longevity factors. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.

Licensing contact

Jennifer Wong
Licensing and Patenting Manager
Office of Technology Transfer
Request more information

Company details

National Institutes of Health (NIH)
NIH achieves its mission of improving human health through a combination of biomedical research, training, and communication.

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Industry sector
Research tools / Cell lines
Therapeutic target
Other therapeutic / Other
Partnering consultation free of charge
Therapeutic Area Partnerships
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us